A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Jiangsu HengRui Medicine Co., Ltd.
Merck Sharp & Dohme LLC
Eli Lilly and Company
Incyte Corporation
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Acrivon Therapeutics
GlaxoSmithKline
Artios Pharma Ltd
Centre Oscar Lambret
City of Hope Medical Center
National Cancer Institute (NCI)
Genmab
Seagen Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Mayo Clinic
Incyte Corporation
ImmunityBio, Inc.
Sutro Biopharma, Inc.
Mural Oncology, Inc
Merck Sharp & Dohme LLC
Incyte Corporation
Jiangsu HengRui Medicine Co., Ltd.
Toray Industries, Inc
Yonsei University
Universitaire Ziekenhuizen KU Leuven
The University of Hong Kong
NGM Biopharmaceuticals, Inc
National Institute of Cancerología
National Institute of Cancerología
National Cancer Institute (NCI)
Esperas Pharma Inc.
AGO Research GmbH
EpicentRx, Inc.
Cyteir Therapeutics, Inc.
Mayo Clinic
Eli Lilly and Company
Grupo Español de Investigación en Cáncer de Ovario
Astex Pharmaceuticals, Inc.
Hospital do Coracao